Written and maintained by CASRAI Editorial Board
Published · Last updated
On this page
The PARI LC Plus is a reusable breath-enhanced jet nebulizer that delivers aerosolized medication directly to the lower respiratory tract. It features a patented dual-valve system that entrains ambient air during patient inhalation to increase aerosol output while minimizing medication loss during exhalation, operating at 3.5 to 8.0 L/min with an MMAD of 3.8 μm.
This page describes products and general use; it is not medical advice.
Short answer
The PARI LC Plus is a reusable breath-enhanced jet nebulizer that delivers aerosolized medication directly to the lower respiratory tract. It features a patented dual-valve system that entrains ambient air during patient inhalation to increase aerosol output while minimizing medication loss during exhalation, operating at 3.5 to 8.0 L/min with an MMAD of 3.8 μm.
Definition and scope
The PARI LC Plus (manufactured by PARI Respiratory Equipment, Inc.) is a reusable small-volume nebulizer (SVN) engineered for the aerosolization of physician-prescribed liquid medications. Under FDA regulations, it is classified as an FDA Class II medical device under 21 CFR § 868.5630 (Nebulizer, Direct Patient Interface) under product code CAF.
The device complies with recognized ISO medical device standards, including ISO 27427:2019 for aerosol characterization (output rate and particle size distribution via cascade impaction) and ISO 5356-1:2015 for standardized 22 mm outer diameter and 15 mm inner diameter conical fittings. The device is cataloged under manufacturer part number 022F81 and billed under Medicare HCPCS code A7005 for non-disposable nebulizer administration sets.
How it works or how it is used in practice
The PARI LC Plus utilizes pneumatic jet atomization paired with breath-enhanced valve dynamics. Compressed air from a medical compressor or hospital gas source enters the base of the nebulizer cup, creating a high-velocity jet stream that draws liquid medication upward via capillary action (Venturi effect). Droplets impact an internal baffle, shearing into a fine aerosol mist.
The breath-enhanced mechanism coordinates aerosol delivery with the patient’s respiratory cycle:
- Inspiratory phase: Negative pressure created during inhalation unseats the flexible silicone inspiratory valve cap at the top of the nebulizer. Ambient room air is entrained into the chimney, accelerating driving airflow and boosting aerosol generation during active inhalation.
- Expiratory phase: Positive pressure during exhalation seats the top inspiratory valve closed, preventing exhaled breath from contaminating the cup. Simultaneously, a one-way silicone flap on the valved mouthpiece opens, venting exhaled gas while eliminating continuous aerosol wastage to the room.
Operation requires a pneumatic driving source providing 3.5 to 8.0 L/min at a minimum operating pressure of 20 psi (1.38 bar), supplied by dedicated compressors (e.g., PRONEB Ultra, Vios) or regulated compressed gas cylinders.
Types or related concepts
PARI manufactures several models within the LC reusable family, each configured for specific aerosol distributions and treatment durations. Sourced performance parameters under standardized testing conditions (1.2 bar compressor, 0.9% NaCl, Malvern MasterSizer X, 20 L/min inspiratory flow, 23° C, 2.5 mL fill) are compared below:
| Specification Parameter | PARI LC PLUS (022F81) | PARI LC Sprint (023F35) | PARI LC STAR (22F50) | Standard Unvented Jet Nebulizer |
|---|---|---|---|---|
| Operating Principle | Breath-enhanced dual valve | Breath-enhanced dual valve | Breath-enhanced fine droplet | Continuous unvented jet |
| Mass Median Diameter (MMAD) | 3.8 μm | 3.5 μm | 3.1 μm | 4.5–6.0 μm |
| Respirable Fraction (%RF < 5 μm) | 65% | 68% | 78% | 35–45% |
| Total Output Rate (TOR) | 440 mg/min | 500 mg/min | 380 mg/min | 200–280 mg/min |
| Average Treatment Duration | 6–7 minutes | ~5 minutes | 8–10 minutes | 12–18 minutes |
| Maximum Fill Capacity | 8.0 mL | 8.0 mL | 6.0 mL | 6.0–10.0 mL |
| Residual Volume | ~0.8 mL | ~0.6 mL | ~0.7 mL | 1.2–1.8 mL |
| HCPCS Billing Code | A7005 (reusable) | A7005 (reusable) | A7005 (reusable) | A7003 (disposable) |
The LC Sprint achieves faster output and smaller residual volume (~0.6 mL) through redesigned jet geometry, while the LC Star produces smaller particles (3.1 μm) designed for deep alveolar targeting.
Where it matters for labs, clinics or supply decisions
The technical characteristics of the PARI LC Plus guide clinical drug trial design, hospital reprocessing, and supply procurement:
1. Clinical Trial Reference Standard
The PARI LC Plus is widely recognized as the regulatory reference nebulizer across major pharmaceutical registration trials. Drug manufacturers standardize on the LC Plus to guarantee reproducible bioequivalence in FDA approvals, including Tobramycin Inhalation Solution (TOBI), Dornase Alfa (Pulmozyme), Budesonide Suspension (Pulmicort Respules), and Revefenacin (Yupelri).
2. Infection Control and Disinfection Protocols
To prevent microbial colonization by pathogens such as Pseudomonas aeruginosa, validated multi-tiered disinfection protocols apply:
- Boiling (Home Care): 5 minutes in rolling boiling water, per Cystic Fibrosis Foundation recommendations.
- Hospital Autoclaving: Disassembled components (excluding PVC tubing and masks) can be steam sterilized in hospital autoclave equipment up to 277° F (136° C).
- Dishwashing: Top-rack placement in an automatic dishwasher basket.
- Chemical Soaking: Immersion in 1:3 distilled white vinegar and hot water for 1 hour, or using quaternary ammonium disinfectant (Control III).
3. Procurement and Lifecycle Management
Under HCPCS A7005, reusable nebulizers are rated for 6 months of continuous service. Compared to disposable units (A7003), reusable polypropylene assemblies maintain precise orifice tolerances across repeated thermal disinfection cycles. Clinics frequently integrate the device with oscillating positive expiratory pressure devices for comprehensive airway clearance.
Common misunderstandings
- Assuming all jet nebulizers deliver equivalent doses: Continuous unvented nebulizers vent medication during exhalation, wasting up to 60% of the dose compared to breath-enhanced valve delivery.
- Washing connecting tubing in water: Tubing should never be submerged. If condensation forms, running the compressor with tubing attached for 2–3 minutes clears moisture.
- Confusing breath-enhanced with breath-actuated nebulizers (BAN): Breath-enhanced units increase flow passively via valves, whereas breath-actuated units mechanically halt aerosol generation during exhalation.
- Treating reusable cups as permanent hardware: Jet orifices erode from thermal washing and mineral scaling; cups must be replaced every 6 months to preserve nominal 3.8 μm MMAD.
- Using underpowered compressors: Driving sources operating under 20 psi or 3.5 L/min cannot generate adequate shearing force, causing particle sizes to exceed respirable ranges (>5 μm).
FAQ
What is the difference between the PARI LC Plus and PARI LC Sprint?
The PARI LC Sprint features updated jet geometry, delivering an average treatment time of ~5 minutes (vs. 6–7 minutes for LC Plus), a smaller droplet size (3.5 μm vs. 3.8 μm MMAD), and lower residual volume (~0.6 mL vs. ~0.8 mL).
What compressor specifications are required to operate the PARI LC Plus?
The compressor or gas source must deliver 3.5 to 8.0 L/min at a minimum operating pressure of 20 psi (1.38 bar) to produce the specified 3.8 μm MMAD aerosol.
How often should the PARI LC Plus reusable nebulizer cup be replaced?
The nebulizer cup and valved mouthpiece should be replaced every 6 months for single-patient home care use to maintain consistent particle distribution and drug delivery rates.
What HCPCS billing code applies to the PARI LC Plus?
The PARI LC Plus is billed under HCPCS code A7005 (“Administration set, with small volume nonfiltered pneumatic nebulizer, non-disposable”).
Can the PARI LC Plus be disinfected in a dishwasher?
Yes. Disassembled cup, insert, valve cap, and mouthpiece parts are top-rack dishwasher safe. The air supply tubing must never be placed in a dishwasher.
Sources
- PARI Respiratory Equipment, Inc. PARI LC PLUS® / LC® STAR Reusable Nebulizer Instructions for Use (Doc # 022D0205 Rev B 04/18). URL: https://www.pari.com. Read 2026-11-11.
- PARI Respiratory Equipment, Inc. The Clinical Choice: Reusable Nebulizer Detail Sheet (Doc # 023D0212 Rev D US-NEB-1800006 v2.0 09-19). URL: https://www.pari.com. Read 2026-11-11.
- PARI Respiratory Equipment, Inc. LC PLUS® Reusable Nebulizer Product Specifications. URL: https://www.pari.com/us/products/nebulizer-cups/lc-plus-reusable-nebulizer/. Read 2026-11-11.
- U.S. Food and Drug Administration (FDA). Medical Device Classification: 21 CFR § 868.5630 (Product Code CAF, Class II). URL: https://www.fda.gov. Read 2026-11-11.
- International Organization for Standardization. ISO 27427:2019: Anaesthetic and respiratory equipment — Nebulizing systems and components. URL: https://www.iso.org. Read 2026-11-11.
- Centers for Medicare & Medicaid Services (CMS). Healthcare Common Procedure Coding System (HCPCS) Code A7005. URL: https://www.cms.gov. Read 2026-11-11.
- Lester, Mary K. “Nebulizer Use and Maintenance by Cystic Fibrosis Patients: A Survey Study.” Respiratory Care 2004; 49(12): 1504–1508. Read 2026-11-11.
- Weigand, et al. “Using RDDR to Compare Delivery Efficiency of Three Commercially Available Breath-Enhanced Nebulizers with Budesonide.” CHEST 2008; 134(4): 112S. Read 2026-11-11.







